ResApp Health expands a clinical study to commercialize its mobile medical applications for the management of respiratory diseases.

The technology has been tested for pneumonia and asthma diagnosis in a clinical proof of concept study of 91 patients by University of Queensland through funding from the Bill and Melinda Gates Foundation.

The technology is based on a machine learning algorithm that uses sound alone to diagnose and measure the severity of a respiratory condition.

The company holds an exclusive licence from the University of Queensland to develop and commercialise mobile medical applications for the diagnosis and management of respiratory diseases.

The addition to the clinical study adds to the existing study currently underway at Joondalup Health Campus that has enrolled more than 150 patients.

View the full story at www.proactiveinvestors.com.au